Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingPRNewsWire • 04/27/22
Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual MeetingPRNewsWire • 04/08/22
Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial ResultsPRNewsWire • 03/24/22
Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting 2022PRNewsWire • 03/08/22
Arcellx Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/08/22
CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19Benzinga • 02/04/22
